A 72-year-old woman with chronic obstructive pulmonary disease (COPD) and benign prostatic hyperplasia (BPH) is admitted to the hospital with acute exacerbation of COPD. She is prescribed ipratropium bromide (an anticholinergic bronchodilator) via nebulizer four times daily. On day 3 of admission, nursing staff report that she has not passed urine for 8 hours, and she complains of severe abdominal discomfort. Bladder ultrasound shows a post-void residual of 450 mL. Which anticholinergic property of ipratropium is responsible for this adverse effect, and what is the most appropriate immediate management?

Explanation

## Anticholinergic-Induced Urinary Retention ### Mechanism of Adverse Effect **Key Point:** Anticholinergic agents block M3 muscarinic receptors on the detrusor (bladder smooth muscle). M3 activation normally causes detrusor contraction and micturition. Blockade of M3 receptors paralyzes the detrusor, preventing bladder emptying and causing acute urinary retention. **High-Yield:** Ipratropium is a quaternary amine anticholinergic bronchodilator used in COPD. Although it has poor systemic absorption due to its quaternary structure, sufficient drug can reach the bladder in susceptible patients (especially elderly with BPH) to cause clinically significant retention. ### Receptor Selectivity and Urinary Effects | Muscarinic Receptor | Location | Function | Effect of Blockade | | --- | --- | --- | --- | | M1 | Salivary glands, CNS | Cognitive, memory | Dry mouth, confusion | | M2 | Heart, airways | Negative chronotropy, bronchoconstriction | Tachycardia, bronchodilation | | M3 | Detrusor, iris, ciliary muscle | Bladder contraction, miosis, accommodation | **Urinary retention, mydriasis, cycloplegia** | | M4 | CNS | Dopamine modulation | Cognitive effects | ### Management of Anticholinergic Urinary Retention **Clinical Pearl:** Acute urinary retention with a post-void residual >450 mL is a medical emergency requiring immediate decompression to prevent bladder rupture and acute kidney injury. #### Step-by-Step Approach: 1. **Discontinue the offending anticholinergic agent** (ipratropium in this case) 2. **Immediate bladder decompression:** - Straight catheterization (preferred if patient can cooperate) - Indwelling Foley catheter if retention is expected to persist 3. **Pharmacologic reversal (if appropriate):** - Bethanechol (M3 agonist): 10–50 mg orally or 2.5–5 mg subcutaneously - Acts as a direct cholinergic agonist to restore detrusor contractility - Contraindicated in mechanical obstruction (e.g., BPH with obstruction) 4. **Manage underlying BPH:** - Consider alpha-blocker (e.g., tamsulosin) or 5-alpha reductase inhibitor - Urology referral if retention persists after anticholinergic withdrawal **Mnemonic:** **CHAMP** = Cholinergic agonists for anticholinergic toxicity: - **C**arbamate esters (physostigmine, neostigmine) - **H**istamine (not relevant here) - **A**cetylcholine agonists (bethanechol, pilocarpine) - **M**uscarinic agonists (bethanechol) - **P**arasympathomimetics (all of the above) ### Why Bethanechol Over Other Options **Tip:** Bethanechol is a selective M3 agonist that directly stimulates detrusor contraction without crossing the BBB (quaternary amine). It is the pharmacologic agent of choice for anticholinergic-induced urinary retention. However, it is **contraindicated** if there is mechanical obstruction (e.g., BPH causing outlet obstruction); in such cases, catheterization alone is safer. **Warning:** Do NOT give anticholinergics (like atropine) to treat anticholinergic toxicity—this worsens the problem. The distractor option suggesting intravenous atropine is a dangerous trap. [cite:KD Tripathi 8e Ch 6; Harrison 21e Ch 48]